Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist from Nasdaq and cease SEC reporting due to compliance costs outweighing the benefits of remaining publicly listed [1][3]. Group 1: Delisting and SEC Reporting - The company plans to file a Form 25 with the SEC around January 30, 2026, with the last trading day on Nasdaq expected to be around February 6, 2026 [2]. - Following the delisting, Venus Concept will file a Form 15 on or about February 9, 2026, which will suspend its obligation to submit periodic SEC reports [2]. Group 2: Financial Position - As of September 30, 2025, the company's inventories were reported at $15.768 million, while cash and equivalents stood at $4.312 million [1]. Group 3: Company Overview - Venus Concept specializes in medical aesthetic technology, offering minimally invasive and non-invasive devices across more than 60 countries, including products like Venus NOVA, Venus Versa, and the ARTAS iX robotic hair restoration system [4]. - The company's stock price fell by 54.83% to $2.00, nearing its 52-week low of $1.39 [4].

Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist its common stock from the NASDAQ Capital Market and deregister its common stock with the SEC, citing that the costs of compliance outweigh the benefits for the company and its shareholders [1][2]. Delisting and Deregistration - The company is compliant with Nasdaq listing requirements but has determined that the resources needed for SEC reporting obligations are excessive compared to the benefits [2]. - Venus Concept has notified Nasdaq of its intent to delist and deregister, planning to file a Form 25 on or about January 30, 2026, with the last trading day expected to be around February 6, 2026 [3]. - A Form 15 will be filed on or about February 9, 2026, which will suspend the company's obligation to file periodic reports with the SEC [3]. Management's Perspective - The Board of Directors believes that this decision is in the best interests of the company and its shareholders, as it will reduce compliance costs and support the execution of the company's turnaround plan [4]. - The CEO of Venus Concept emphasized the collaboration with Madryn Asset Management to position the company for long-term financial success [4]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products, reaching over 60 countries [5]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [5].

Core Viewpoint - Venus Concept Inc. (NASDAQ:VERO) experienced a significant stock price increase of over 500% on Friday, driven by high trading volume and strategic investment developments [1]. Group 1: Stock Performance - Venus Concept stock surged 593.01% to $9.91 at publication, with a trading volume of 223.09 million shares compared to an average volume of 1.74 million [1][6]. Group 2: Major Stake Acquisition - Madryn Asset Management disclosed a 91% stake in Venus Concept, indicating the investment is for strategic purposes [2]. - As a major shareholder, Madryn Asset Management plans to engage actively in operational, financial, and strategic initiatives, including evaluating potential strategic alternatives for the company [3]. Group 3: Financial Performance - Venus Concept reported third-quarter sales of $13.78 million, which fell short of the consensus estimate of $14.48 million, marking an 8% year-over-year decline and a 12% quarter-over-quarter decline, primarily due to a downturn in the Hair Restoration business [4]. Group 4: Product Development - The U.S. FDA granted 510(k) clearance to Venus Concept's Venus NOVA, a next-generation multi-application platform aimed at enhancing non-invasive treatments for various aesthetic applications [5]. - Venus NOVA features Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF), Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse technology, providing a comprehensive solution for body contouring and skin treatments [6].

Core Viewpoint - Venus Concept Inc. reported financial results for Q3 2025, highlighting challenges in the aesthetics market but showing signs of stabilization in its Energy Based Device (EBD) business. The company is focused on long-term success through cash management and targeted investments, alongside a new product launch and ongoing strategic transactions [3][5]. Financial Results Summary - Total revenue for Q3 2025 was $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter, primarily due to a decline in the Hair Restoration business [5][6]. - EBD revenues showed signs of stabilization with total sales of $9.6 million, up 2% year-over-year [5]. - GAAP net loss for Q3 2025 was $22.5 million, compared to a loss of $9.3 million in Q3 2024. Adjusted EBITDA loss was $7.8 million, compared to a loss of $5.9 million in the prior year [5][11]. Revenue Breakdown - U.S. revenue decreased by $1.1 million, or 12%, year-over-year, while international revenue decreased by $0.2 million, or 3% [6][7]. - Revenue by product category showed a 12% decrease in products – systems revenue, a 15% decrease in products – other revenue, and a 5% decrease in services revenue, partially offset by a 9% increase in lease systems revenue [7]. Operating Performance - Gross profit for Q3 2025 decreased by $1.1 million, or 11%, to $8.8 million, with a gross margin of 64.0%, down from 66.1% in Q3 2024 [8]. - Operating expenses increased by $1.2 million, or 7%, to $18.3 million, driven by higher general and administrative and selling and marketing expenses [9]. Strategic Developments - The company announced FDA 510(k) clearance for the Venus NOVA, its next-generation multi-application platform, marking a significant step in its R&D strategy [5]. - The company is actively pursuing the sale of its Venus Hair Business, facing challenges with the counterparty and seeking court assistance to close the transaction [3]. Balance Sheet and Cash Flow - As of September 30, 2025, the company had cash and cash equivalents of $5.9 million and total debt obligations of approximately $30.1 million, a reduction from $39.7 million at the end of 2024 [11]. - The company executed a debt-to-equity exchange transaction totaling $11.5 million, resulting in a 24% reduction in total debt compared to December 31, 2024 [5].

Core Insights - Venus Concept Inc. has received FDA 510(k) clearance for its new product, Venus NOVA, marking a significant milestone in the company's R&D strategy [1][3] - Venus NOVA is designed to provide a comprehensive solution for non-invasive body, face, and skin treatments, integrating multiple advanced technologies [2][3] Product Features - Venus NOVA incorporates Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF) combined with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology [2][4] - The platform aims to enhance body contouring, muscle conditioning, skin treatments, and reduce wrinkles and cellulite [2] Strategic Initiatives - The launch of Venus NOVA aligns with the company's turnaround strategy initiated in 2023 and the Venus AI strategic initiative, focusing on innovation and customer partnerships [3] - The product is expected to support the growing demand for aesthetic treatments, particularly for patients using GLP-1 medications, with an anticipated increase to over 32 million users globally by 2030 [3] Market Positioning - Venus NOVA is positioned to penetrate the multi-billion-dollar body and skin market, contributing to the company's long-term growth profile [3] - The product will be available in the U.S. starting December 2025, with global rollouts planned for 2026 and beyond [6] Support Programs - The Venus Jumpstart Program will provide a 30-day roadmap for advanced clinical education and marketing enablement to ensure successful integration of Venus NOVA into existing practices [4][5]